Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly

被引:151
|
作者
Yamamoto, K
Takeshita, K
Kojima, T
Takamatsu, J
Saito, H
机构
[1] Nagoya Univ, Dept Transfus Med, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Dept Cardiol, Grad Sch Med, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Dept Med Technol, Sch Hlth Sci, Nagoya, Aichi 4668550, Japan
[4] Nagaya Med Ctr, Nagoya, Aichi 4668550, Japan
关键词
PAI-1; obesity; stress; immune response; vascular remodeling;
D O I
10.1016/j.cardiores.2004.11.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombotic cardiovascular diseases increase in incidence in the elderly, a tendency dependent on the age-related changes in vascular and hemostatic systems that include platelets, coagulation, and fibrinolytic factors as well as in the endothelium. The hypercoagulability of and advanced sclerotic changes in the vascular wall may contribute to the increased incidence of thrombosis in the elderly. One of the important key genes for aging-associated thrombosis is plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis. The expression of PAI-1 is not only elevated in the elderly but also significantly induced in a variety of pathologies associated with the process of aging. These conditions include obesity, insulin resistance, emotional stress, immune responses, and vascular sclerosis/remodeling. Several cytokines and hormones, including tumor necrosis factor-alpha, transforming growth factor-beta, angiotensin II, and insulin, positively regulate the gene expression of PAI-1. The recent epidemic in obesity with aging in the industrialized society may heighten the risk for thrombotic cardiovascular disease because adipose tissue is a primary source of PAI-1 and cytokines. Emotional or psychosocial stress and inflammation also cause the elevated expression of PAI-1 in an age-specific pattern. Thus, PAI-1 could play a key role in the progression of cardiovascular aging by promoting thrombosis and vascular (athero)sclerosis. Further studies on the genetic mechanism of aging-associated PAI-1 induction will be necessary to define the basis for cardiovascular aging in relation to thrombosis. (c) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:276 / 285
页数:10
相关论文
共 50 条
  • [21] Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?
    Montoro-Garcia, Silvia
    Marin, Francisco
    Roldan, Vanessa
    Lip, Gregory Y. H.
    THROMBOSIS RESEARCH, 2011, 128 (06) : 601 - 602
  • [22] THE ACTIVITY OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) OF HUMAN PLATELET
    BOOTH, NA
    CROLL, A
    BENNETT, B
    FIBRINOLYSIS, 1990, 4 : 138 - 140
  • [23] Purinergic regulation of plasminogen activator inhibitor-1 (PAI-1) expression in vascular smooth muscle cells
    Feener, EP
    Bouchie, JL
    Chen, HC
    Wilden, PA
    Bagot, C
    CIRCULATION, 1999, 100 (18) : 747 - 747
  • [24] Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients
    Kowal, Krzysztof
    Zukowski, Sebastian
    Moniuszko, Marcin
    Bodzenta-Lukaszyk, Anna
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2008, 46 (02) : 193 - 198
  • [25] Do plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator PAI-1 complexes (tPA-PAI-1) Predict complications in type 1 diabetes (TID)?
    Bosnyak, Z
    Forrest, KYZ
    Maser, RE
    Orchard, TJ
    DIABETES, 2001, 50 : A209 - A209
  • [26] The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals
    Verschuur, M
    Jellema, A
    Bladbjerg, EM
    Feskens, EJM
    Mensink, RP
    Moller, L
    Vos, HL
    de Maat, MPM
    ATHEROSCLEROSIS, 2005, 181 (02) : 275 - 284
  • [27] Role of plasminogen activator inhibitor-1 (PAI-1) in regulating the pathogenesis of S. aureus arthritis via plasminogen pathway
    Sultana, Sahin
    Dey, Rajen
    Bishayi, Biswadev
    IMMUNOLOGY LETTERS, 2019, 209 : 53 - 66
  • [28] THE CHARACTERIZATION OF A NOVEL INHIBITOR OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN-VITRO
    FAINT, RW
    CHARLTON, P
    BENT, F
    BRYANS, J
    MACKIE, I
    BEVAN, P
    BLOOD, 1994, 84 (10) : A73 - A73
  • [29] Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in essential thrombocythemia and polycythemia vera and thrombotic complications.
    Cacciola, Rossella R.
    Di Francesco, Ernesto
    Giustolisi, Rosario
    Cacciola, Emma
    BLOOD, 2006, 108 (11) : 306B - 306B
  • [30] Plasminogen Activator Inhibitor-1 (PAI-1) deficiency predisposes to depression and resistance to treatments
    Hélène Party
    Cléo Dujarrier
    Marie Hébert
    Sophie Lenoir
    Sara Martinez de Lizarrondo
    Raphaël Delépée
    Claudine Fauchon
    Marie-Christine Bouton
    Pauline Obiang
    Olivier Godefroy
    Etienne Save
    Laurent Lecardeur
    Joëlle Chabry
    Denis Vivien
    Véronique Agin
    Acta Neuropathologica Communications, 7